ABBVIE
A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 161
- Registration Number
- NCT06308198
- Locations
- 🇨🇳
Beijing Hospital /ID# 256084, Beijing, Beijing, China
🇯🇵Tokyo Center Clinic /ID# 267380, Chuo-ku, Tokyo, Japan
🇨🇳Dermatology Hospital of Southern Medical University /ID# 256172, Guangzhou, Guangdong, China
Study of Oral ABBV-932 Capsules to Evaluate Dopamine D2 and D3 Receptor Occupancy in Brain in Adult Healthy Volunteers
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 12
- Registration Number
- NCT06300580
- Locations
- 🇬🇧
Parexel Early Phase Clinical Unit /ID# 264286, Harrow, United Kingdom
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Conditions
- Interventions
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 80
- Registration Number
- NCT06291220
- Locations
- 🇦🇺
Royal Perth Hospital /ID# 256464, Perth, Western Australia, Australia
🇺🇸City of Hope /ID# 253904, Duarte, California, United States
🇺🇸City of Hope Orange County Lennar Foundation Cancer Center /ID# 267158, Irvine, California, United States
A Study to Assess the Mass Balance of [14C] ABBV-552 in Healthy Male Participants Following Single Oral Dose Administration
- First Posted Date
- 2024-02-26
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 8
- Registration Number
- NCT06278766
- Locations
- 🇺🇸
Fortrea Clinical Research Unit Inc /ID# 262684, Madison, Wisconsin, United States
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 200
- Registration Number
- NCT06257875
- Locations
- 🇵🇱
Centrum Medyczne Melita Medical /ID# 258379, Wrocław, Dolnoslaskie, Poland
🇵🇱Centrum Medyczne LukaMed Joanna Luka /ID# 258457, Chojnice, Pomorskie, Poland
🇵🇷Caribbean Medical Research Center /ID# 268395, San Juan, Puerto Rico
Observational Study of Oral Cariprazine Capsules to Assess Change in Disease Activity in Adult Participants With Bipolar I Disorder
- Conditions
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 170
- Registration Number
- NCT06256367
- Locations
- 🇨🇦
Southlake Regional Health Centre /ID# 264212, Newmarket, Ontario, Canada
🇨🇦START Clinic for Mood and Anxiety Disorders /ID# 262416, Toronto, Ontario, Canada
🇨🇦Institut universitaire en santé mentale de Montréal /ID# 264665, Montreal, Quebec, Canada
Study to Evaluate the Effectiveness of Risankizumab in Participants With a Recent Diagnosis of Moderate Plaque Psoriasis in a Real-life Setting in Greece
- Conditions
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 250
- Registration Number
- NCT06247319
- Locations
- 🇬🇷
University General Hospital of Heraklion /ID# 268777, Heraklion, Greece
🇬🇷General Hospital of Thessaloniki "Agios Pavlos'' /ID# 267506, Thessaloniki, Greece
🇬🇷Olympion General Clinic /ID# 266258, Patras, Achaia, Greece
Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1300
- Registration Number
- NCT06241313
- Locations
- 🇩🇪
Studienzentrum Nord-West /ID# 258024, Westerstede, Niedersachsen, Germany
🇩🇪Universitaetsklinikum Duesseldorf /ID# 258078, Düsseldorf, Nordrhein-Westfalen, Germany
🇩🇪AmBeNet GmbH /ID# 258075, Leipzig, Sachsen, Germany
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 840
- Registration Number
- NCT06236438
- Locations
- 🇺🇸
University of Kansas Medical Center /ID# 263196, Westwood, Kansas, United States
🇺🇸Memorial Hospital West /ID# 262221, Pembroke Pines, Florida, United States
🇺🇸Bond Clinic /ID# 262611, Winter Haven, Florida, United States
Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 55
- Registration Number
- NCT06223516
- Locations
- 🇺🇸
Atrium Health Wake Forest Baptist Medical Center /ID# 260807, Winston-Salem, North Carolina, United States
🇯🇵Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital /ID# 265286, Nagoya, Aichi, Japan
🇯🇵Kindai University Hospital /ID# 266016, Osakasayama-shi, Osaka, Japan